



(51) International Patent Classification:

A61K 39/29 (2006.01) C07K 14/02 (2006.01)
A61K 36/06 (2006.01)

(21) International Application Number:

PCT/US2012/042426

(22) International Filing Date:

14 June 2012 (14.06.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/497,039 14 June 2011 (14.06.2011) US

(71) Applicant (for all designated States except US):

GLOBEIMMUNE, INC. [US/US]; 1450 Infinite Drive,
Louisville, CO 80027 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KING, Thomas, H.
[US/US]; 4105 Perry Street, Denver, CO 80212 (US).
APELIAN, David [US/US]; 3 Old Beach Glen Road,
Boonton Township, NJ 07005 (US).

(74) Agent: DOMITROVICH, Angela, M.; SHERIDAN
ROSS P.C., 1560 Broadway, Suite 1200, Denver, CO
80202 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: YEAST-BASED COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF HEPATITIS
DELTA VIRUS INFECTION

FIG. 1

```

_genotype1 -NGRKKLEDLERDLRKKKKKKKLEDENPWLGNLGIILCKKDKDGEAPPKARARTDQME 59
_genotype2 VSTRKKAEELELDLRKARKTIKRLDNDPWLGNLGIIRK-GKDGEAPPKARARTDQME 59
_genotype3 VEERKKNRKKLEKDLRRANKKKKLEDENPWLGNVVGILLRR-KKDEDGAPPKARPRQETME 59
      . ** : ..**:**: .*,**:**:*****: *:: : ** :*****,* : **

_genotype1 IDSGPGRPLRGGSFSDKERQDHRRKALENKRKQLAAGGKHLSEEEEELKRLETEEDER 119
_genotype2 VDSGPRKPKHSGFTDKERQDHRRKALQMKNLQAGGKSLSEEEEELRRLTIEDDER 119
_genotype3 VDSGPGRKPKARGFTDQERRDHRRKALENKKQLAGGKHLSEEEEELRRLARDDDER 119
      :**** :;* **:*:**:*****:**:***.*** **:******:**: :*:.*

_genotype1 EERTAGPSVGGVNPLEGGSRG 140
_genotype2 QRRVAGPRVGVNPPGGSPRG 140
_genotype3 EERTAGPRPGGVNPDGPPRG 140
      :**.*** *.*** *.***

```

(57) Abstract: Disclosed are immunotherapeutic compositions and methods for preventing and/or treating hepatitis delta virus (HDV) infection, including yeast-based HDV immunotherapeutic compositions and methods of use of such compositions to prevent and/or treat HDV infection and symptoms and sequela thereof.